CIP2A Antibodies
We offer CIP2A Antibodies for use in common research applications: Flow Cytometry, Immunocytochemistry/Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Paraffin, Immunoprecipitation, Western Blot. Each CIP2A Antibody is fully covered by our Guarantee+, to give you complete peace of mind and the support when you need it. Our CIP2A Antibodies can be used in a variety of model species: Human, Mouse, Primate, Rat. Use the list below to choose the CIP2A Antibody which is most appropriate for your research; you can click on each one to view full technical details, images, references, reviews and related products. Choose from our CIP2A polyclonal antibodies and browse our CIP2A monoclonal antibody catalog.
Alternate Names for CIP2A Antibodies
anti-CIP2A antibody, anti-KIAA1524 antibody, anti-Cancerous inhibitor of PP2A antibody, anti-FLJ12850 antibody, anti-MGC163436 antibody, anti-p90 antibody, anti-p90 autoantigen antibody, anti-protein CIP2A antibody
6 Results for "cip2a" in Primary Antibodies
![Knockdown Validated: CIP2A Antibody (2G10) [NB110-59722] - miR-375 increases p21, p53, and RB in HPV16- and 18-positive cancer. Protein levels of CIP2A, p53, and p21 in SiHa cells transfected with si-CIP2A and/or si-p53 were measured by Western blot analysis. Protein levels of CIP2A, p53, and p21 in SiHa cells transfected with si-p53 and/or miR-375-mimic were measured by Western blot analysis. Image collected and cropped by CiteAb from the following publication (//molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-13-80) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CIP2A-Antibody-2G10-Knockdown-Validated-NB110-59722-img0013.jpg "<b>Genetic Strategies Validation. </b>Knockdown Validated: CIP2A Antibody (2G10) [NB110-59722] - miR-375 increases p21, p53, and RB in HPV16- and 18-positive cancer. Protein levels of CIP2A, p53, and p21 in SiHa cells transfected with si-CIP2A and/or si-p53 were measured by Western blot analysis. Protein levels of CIP2A, p53, and p21 in SiHa cells transfected with si-p53 and/or miR-375-mimic were measured by Western blot analysis. Image collected and cropped by CiteAb from the following publication (//molecular-cancer.biomedcentral.com/articles/10.1186/1476-4598-13-80) licensed under a CC-BY license.")
![<b>Genetic Strategies Validation. </b>Flow Cytometry: CIP2A Antibody (2G10) [NB110-59722] - Intracellular flow cytometric staining of 1 x 10^6 CHO (A) and HEK-293 (B) cells using CIP2A antibody (dark blue). Isotype control shown in orange. An antibody concentration of 1 ug/1x10^6 cells was used.](http://images.novusbio.com/fullsize/CIP2A-Antibody-2G10-Flow-Cytometry-NB110-59722-img0011.jpg)
![Western Blot: CIP2A Antibody (2G10) [NB110-59722] - Detection of CIP2A in HeLa whole cell lysate.](http://images.novusbio.com/fullsize/CIP2A-Antibody-2G10-Western-Blot-NB110-59722-img0004.jpg)
![Western Blot: CIP2A Antibody (2G10) [NB110-59722] - Analysis of CIP2A in NIH/3T3 cell lysate.](http://images.novusbio.com/fullsize/CIP2A-Antibody-2G10-Western-Blot-NB110-59722-img0001.jpg)
![Immunocytochemistry/Immunofluorescence: CIP2A Antibody (2G10) [NB110-59722] - CIP2A antibody was tested in U2OS cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/CIP2A-Antibody-2G10-Immunocytochemistry-Immunofluorescence-NB110-59722-img0005.jpg)
![Immunohistochemistry-Paraffin: CIP2A Antibody (2G10) [NB110-59722] - IHC analysis of formalin fixed paraffin-embedded (FFPE) human colon cancer using CIP2A antibody at 1:200 on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) using 10mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching with peroxide block. The sections were incubated with primary antibody for 30 minutes and Bond Polymer Refine Detection (Leica Biosystems) with DAB was used for signal development followed by counterstaining with hematoxylin. Whole slide scanning and capturing of representative images was performed using Aperio AT2 (Leica Biosystems). Staining was performed by Histowiz.](http://images.novusbio.com/fullsize/CIP2A-Antibody-2G10-Immunohistochemistry-Paraffin-NB110-59722-img0012.jpg)
![Western Blot: CIP2A Antibody (2G10) [NB110-59722] - miR-375 increases p21, p53, & RB in HPV16- & 18-positive cancer. (A) Protein levels of p21, p53, & RB in SiHa cells transfected w/ miR-375 inhibitor, -mimic, or NS control measured by Western blot analysis. 25%, 50%, 100% amounts of untreated cell lysates included to calibrate the semiquantitative measurement. (B) Relative endogenous mRNA levels of p21, p53, & RB measured in SiHa cells transfected w/ miR-375 inhibitor, -mimic, or NS control using qRT-PCR. (C) One hundred thousand SiHa cells seeded on 24-well plate & the number of cells counted by trypan blue exclusion staining assay 48 h post-transfection. (D) Protein levels of p21, p53, & RB in HeLa cells transfected w/ miR-375 inhibitor, -mimic, or NS control measured by Western blot analysis. (E) Relative p21 mRNA levels measured in HeLa cells transfected w/ miR-375 inhibitor, -mimic, or NS control. (F) Trypan blue exclusion staining assay used to analyze the proliferation rate of HeLa cells 48 h post-transcfection. (G) Flow cytometry analysis demonstrates G1 arrest of SiHa cells 48 h after transfection w/ miR-375-mimic compared to miR-375 inhibitor or NS control. (H) Protein levels of CIP2A, p53, & p21 in SiHa cells transfected w/ si-CIP2A and/or si-p53 measured by Western blot analysis. (I) Protein levels of CIP2A, p53, & p21 in SiHa cells transfected w/ si-p53 and/or miR-375-mimic measured by Western blot analysis. (J) mRNA levels of p21 in SiHa cells transfected w/ si-p53 and/or miR-375-mimic measured by qRT-PCR. The concentrations of siRNA or miRNA used in panels H, I, & J 10 nM & 25 nM, respectively. Results are expressed as mean ± SD from three independent experiments. *p < 0.05, ***p < 0.001, & ****p < 0.0001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24708873), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-59722_mouse-monoclonal-cip2a-antibody-2g10-310202416205141.jpg)
![Western Blot: CIP2A Antibody (2G10) [NB110-59722] - miR-375 control on CIP2A-MYC pathway also contributes to p21 elevation. (A) p21, p53, RB, CIP2A, & MYC protein levels in MCF7 cells transfected with miR-375 inhibitor, -mimic, or NS control were measured by Western blot analysis. Tubulin expression was used as internal control. 25%, 50%, 100% amounts of untreated cell lysates were included to calibrate the semiquantitative measurement. (B) Transfection with miR-375-mimic significantly upregulated p21 mRNA in MCF7. Relative endogenous p21 mRNA levels were measured in MCF7 cells transfected with miR-375 inhibitor, -mimic, or NS control for 48 h using qRT-PCR. (C) CIP2A & MYC protein levels were effectively silenced by si-CIP2A transfection with 1 & 10 nM concentrations for 48 h. Increased p21 protein levels were detected in si-CIP2A dose-dependent manner. 10 nM of si-GFP was used as a control. (D) Protein levels of CIP2A, p53, & p21 in MCF7 cells transfected with si-p53 and/or miR-375-mimic were measured by Western blot analysis. (E) mRNA levels of p21 in MCF7 cells transfected with si-p53 and/or miR-375-mimic were measured by qRT-PCR. (F) Flow cytometry analysis demonstrates G1 arrest of MCF7 cells 48 h after transfection with miR-375-mimic compared to miR-375 inhibitor or NS control. The concentrations of siRNA or miRNA used in panels D, E, & F were 10 nM & 25 nM, respectively. (G) Schematic depiction of miR-375-mediated repression of CIP2A, E6, E6AP, & E7 in HPV16-positive cells that simultaneously increases tumor suppressor p53, p21, & RB, & causes cell cycle arrest. Results are expressed as mean ± SD from three independent experiments. *p < 0.05, **p < 0.01, & ***p < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24708873), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-59722_mouse-monoclonal-cip2a-antibody-2g10-310202416205185.jpg)
![Western Blot: CIP2A Antibody (2G10) [NB110-59722] - miR-375-mediated repression of HPV16, E6AP, & CIP2A activates the p53-p21 network & suppresses telomerase activity. (A) miR-375 demonstrates upregulation of p53 & p21 comparable to that of the single or combined CIP2A, E6, & E6AP knockdown. CIP2A, E6AP, p53, & p21 protein levels in SiHa cells transfected with siRNA targeting CIP2A, HPV16-E6, & E6AP (si-CIP2A, si-E6, & si-E6AP, respectively) were analyzed by Western blot. 1 nM & 10 nM siRNA concentrations & 5 nM & 50 nM for miR-375-mimic were used for transfection. si-Three is a combination of the three siRNAs indicated above. 10 nM of si-GFP was used as a control. Tubulin expression was used as internal control. (B) The increase in p21 protein levels correlate to its mRNA levels. Relative endogenous p21 mRNA levels transfected with siRNAs or miR-375 were measured using qRT-PCR. (C) miR-375 exerted a similar or stronger reduction in TERT mRNA levels when compared to E6 & E6AP knockdown in SiHa cells. (D) SiHa cells transfected with miR-375-mimic significantly reduced telomerase activity. Relative telomerase activities in SiHa cells transfected with NS control, miR-375-mimic, & miR-375 inhibitor were measured by SYBR real-time PCR TRAP assay. Heat-inactivated telomerase extracts were used to normalize this data. *p < 0.05, **p < 0.01, ***p < 0.001, & ****p < 0.0001. ns, not significant. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24708873), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-59722_mouse-monoclonal-cip2a-antibody-2g10-31020241620514.jpg)
![Western Blot: CIP2A Antibody (2G10) [NB110-59722] - miR-375 control on CIP2A-MYC pathway also contributes to p21 elevation. (A) p21, p53, RB, CIP2A, & MYC protein levels in MCF7 cells transfected with miR-375 inhibitor, -mimic, or NS control were measured by Western blot analysis. Tubulin expression was used as internal control. 25%, 50%, 100% amounts of untreated cell lysates were included to calibrate the semiquantitative measurement. (B) Transfection with miR-375-mimic significantly upregulated p21 mRNA in MCF7. Relative endogenous p21 mRNA levels were measured in MCF7 cells transfected with miR-375 inhibitor, -mimic, or NS control for 48 h using qRT-PCR. (C) CIP2A & MYC protein levels were effectively silenced by si-CIP2A transfection with 1 & 10 nM concentrations for 48 h. Increased p21 protein levels were detected in si-CIP2A dose-dependent manner. 10 nM of si-GFP was used as a control. (D) Protein levels of CIP2A, p53, & p21 in MCF7 cells transfected with si-p53 and/or miR-375-mimic were measured by Western blot analysis. (E) mRNA levels of p21 in MCF7 cells transfected with si-p53 and/or miR-375-mimic were measured by qRT-PCR. (F) Flow cytometry analysis demonstrates G1 arrest of MCF7 cells 48 h after transfection with miR-375-mimic compared to miR-375 inhibitor or NS control. The concentrations of siRNA or miRNA used in panels D, E, & F were 10 nM & 25 nM, respectively. (G) Schematic depiction of miR-375-mediated repression of CIP2A, E6, E6AP, & E7 in HPV16-positive cells that simultaneously increases tumor suppressor p53, p21, & RB, & causes cell cycle arrest. Results are expressed as mean ± SD from three independent experiments. *p < 0.05, **p < 0.01, & ***p < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24708873), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb110-59722_mouse-monoclonal-cip2a-antibody-2g10-31020241621848.jpg)
![Western Blot: CIP2A Antibody [NB100-74663] - CIP2A downregulation reduces proliferation and induces apoptosis in melanoma cells. Immunoblot analysis showing reduction in cancerous inhibitor of protein phosphatase 2A protein levels 48 h post siRNA transfection and effects on proliferation and apoptosis markers. The figure is representative of at last three independent biological experiments. Image collected and cropped by CiteAb from the following publication (//doi.wiley.com/10.1002/cam4.425), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CIP2A-Antibody-Western-Blot-NB100-74663-img0011.jpg "<b>Genetic Strategies Validation. </b>Western Blot: CIP2A Antibody [NB100-74663] - CIP2A downregulation reduces proliferation and induces apoptosis in melanoma cells. Immunoblot analysis showing reduction in cancerous inhibitor of protein phosphatase 2A protein levels 48 h post siRNA transfection and effects on proliferation and apoptosis markers. The figure is representative of at last three independent biological experiments. Image collected and cropped by CiteAb from the following publication (//doi.wiley.com/10.1002/cam4.425), licensed under a CC-BY license.")
![<b>Genetic Strategies Validation. </b>Immunohistochemistry: CIP2A Antibody [NB100-74663] - Characterization of CIP2A expression in a panel of normal human melanocytes (NHM) and melanoma cell lines. Cytoplasmic and nuclear expression of CIP2A in normal melanocytes, primary and metastatic melanoma cell lines assessed by immunohistochemical staining. CIP2A = cancerous inhibitor of protein phosphatase 2A. Image collected and cropped by CiteAb from the following publication (//doi.wiley.com/10.1002/cam4.425), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CIP2A-Antibody-Immunohistochemistry-NB100-74663-img0012.jpg)
![Western Blot: CIP2A Antibody [NB100-74663] - Characterization of CIP2A expression in a panel of normal human melanocytes (NHM) and melanoma cell lines. Immunoblot analysis of protein expression levels of CIP2A. Image collected and cropped by CiteAb from the following publication (//doi.wiley.com/10.1002/cam4.425), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CIP2A-Antibody-Western-Blot-NB100-74663-img0009.jpg)
![Western Blot: CIP2A Antibody [NB100-74663] - Characterization of CIP2A expression in a panel of normal human melanocytes (NHM) and melanoma cell lines. Cytoplasmic and nuclear expression of CIP2A in normal melanocytes, primary and metastatic melanoma cell lines assessed by immunoblot analysis. CIP2A = cancerous inhibitor of protein phosphatase 2A. Image collected and cropped by CiteAb from the following publication (//doi.wiley.com/10.1002/cam4.425), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CIP2A-Antibody-Western-Blot-NB100-74663-img0010.jpg)
![Immunohistochemistry: CIP2A Antibody [NB100-74663] - Section of human colon carcinoma. Antibody: Affinity purified rabbit anti-CIP2A used at a dilution of 1:100. Detection: Red-fluorescent goat anti-rabbit IgG highly cross-adsorbed Antibody used at a dilution of 1:100.](http://images.novusbio.com/fullsize/CIP2A-Antibody-Immunohistochemistry-NB100-74663-img0008.jpg)
![Immunohistochemistry-Paraffin: CIP2A Antibody [NB100-74663] - Section of human colon carcinoma. Antibody: Affinity purified rabbit anti-CIP2A used at a dilution of 1:250. Detection: DAB](http://images.novusbio.com/fullsize/CIP2A-Antibody-Immunohistochemistry-Paraffin-NB100-74663-img0006.jpg)
![Immunohistochemistry-Paraffin: CIP2A Antibody [NB100-74663] - Section of human ovarian carcinoma. Antibody: Affinity purified rabbit anti-CIP2A used at a dilution of 1:250. Detection: DAB](http://images.novusbio.com/fullsize/CIP2A-Antibody-Immunohistochemistry-Paraffin-NB100-74663-img0007.jpg)
![Western Blot: CIP2A Antibody [NB100-74663] - CIP2A is an inhibitor of PP2A-mediated DAPK dephosphorylationRSC96 cells were transfected with control, CIP2A siRNA (A), DKK-CIP2A (B), or DAPK siRNA (C) for 48 h & then exposed to GAS6 (100 ng/ml) for 30 min. PP2A activity & immunoblotting evaluations of DKK, CIP2A, pDAPK, & DAPK were performed. (D) RSC96 cells were incubated with GAS6 (100 ng/ml) for 30 min & co-immunoprecipitation between CIP2A, pDAPK & PP2A was evaluated. Immunoprecipitated PP2A activity was measured. Data are the mean ± SD, & n = 3 for each time point. * p < 0.05, ** p < 0.01, vs. control. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.23978), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-74663_rabbit-polyclonal-cip2a-antibody-310202415384132.jpg)
![Western Blot: CIP2A Antibody [NB100-74663] - CIP2A is an inhibitor of PP2A-mediated DAPK dephosphorylationRSC96 cells were transfected with control, CIP2A siRNA (A), DKK-CIP2A (B), or DAPK siRNA (C) for 48 h & then exposed to GAS6 (100 ng/ml) for 30 min. PP2A activity & immunoblotting evaluations of DKK, CIP2A, pDAPK, & DAPK were performed. (D) RSC96 cells were incubated with GAS6 (100 ng/ml) for 30 min & co-immunoprecipitation between CIP2A, pDAPK & PP2A was evaluated. Immunoprecipitated PP2A activity was measured. Data are the mean ± SD, & n = 3 for each time point. * p < 0.05, ** p < 0.01, vs. control. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.23978), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-74663_rabbit-polyclonal-cip2a-antibody-310202415171316.jpg)
![Western Blot: CIP2A Antibody [NB100-74663] - GAS6 increases the amount of both CIP2A & p-DAPK in RSC96 cells(A) RSC96 cells were incubated with GAS6 (100 ng/ml), & immunoblotting evaluations of CIP2A & p-DAPK expression were performed. The lower panel shows the intensity during basal conditions from the scanned imaged (upper panel). (B) RSC96 cells incubated with & without GAS6 (100 ng/ml) for 30 min & analysed by immunofluorescence. (C) Immunohistochemistry images demonstrated that CIP2A expression levels were higher than sham levels at 14 days & 28 days in the cavernous nerve after BCNI. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.23978), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-74663_rabbit-polyclonal-cip2a-antibody-310202415304268.jpg)
![Western Blot: CIP2A Antibody [NB100-74663] - CIP2A is an inhibitor of PP2A-mediated DAPK dephosphorylationRSC96 cells were transfected with control, CIP2A siRNA (A), DKK-CIP2A (B), or DAPK siRNA (C) for 48 h & then exposed to GAS6 (100 ng/ml) for 30 min. PP2A activity & immunoblotting evaluations of DKK, CIP2A, pDAPK, & DAPK were performed. (D) RSC96 cells were incubated with GAS6 (100 ng/ml) for 30 min & co-immunoprecipitation between CIP2A, pDAPK & PP2A was evaluated. Immunoprecipitated PP2A activity was measured. Data are the mean ± SD, & n = 3 for each time point. * p < 0.05, ** p < 0.01, vs. control. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.23978), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-74663_rabbit-polyclonal-cip2a-antibody-310202415382441.jpg)
![Western Blot: CIP2A Antibody [NB100-74663] - GAS6 triggers p-Axl, p-DAPK & CIP2A to form a protein complex in RSC96 cells(A-B) Co-immunoprecipitation between p-Axl, p-DAPK & CIP2A with GAS6 stimulation for 30 min in RSC96 cells. Total lysate indicates 1/10 input in each experiment. The relative quantification of protein expression was normalized with respect to beta -actin expression. (C) Immunofluorescence image demonstrating co-localized CIP2A & p-Axl & co-localized p-Axl & p-DAPK (D) after GAS6 stimulation for 30 min in RSC96 cells. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.23978), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-74663_rabbit-polyclonal-cip2a-antibody-31020241539737.jpg)
![Western Blot: CIP2A Antibody [NB100-74663] - CIP2A is an inhibitor of PP2A-mediated DAPK dephosphorylationRSC96 cells were transfected with control, CIP2A siRNA (A), DKK-CIP2A (B), or DAPK siRNA (C) for 48 h & then exposed to GAS6 (100 ng/ml) for 30 min. PP2A activity & immunoblotting evaluations of DKK, CIP2A, pDAPK, & DAPK were performed. (D) RSC96 cells were incubated with GAS6 (100 ng/ml) for 30 min & co-immunoprecipitation between CIP2A, pDAPK & PP2A was evaluated. Immunoprecipitated PP2A activity was measured. Data are the mean ± SD, & n = 3 for each time point. * p < 0.05, ** p < 0.01, vs. control. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.23978), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-74663_rabbit-polyclonal-cip2a-antibody-310202415175242.jpg)
![Immunohistochemistry-Paraffin: CIP2A Antibody [NB100-74663] - GAS6 increases the amount of both CIP2A & p-DAPK in RSC96 cells(A) RSC96 cells were incubated with GAS6 (100 ng/ml), & immunoblotting evaluations of CIP2A & p-DAPK expression were performed. The lower panel shows the intensity during basal conditions from the scanned imaged (upper panel). (B) RSC96 cells incubated with & without GAS6 (100 ng/ml) for 30 min & analysed by immunofluorescence. (C) Immunohistochemistry images demonstrated that CIP2A expression levels were higher than sham levels at 14 days & 28 days in the cavernous nerve after BCNI. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.23978), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-74663_rabbit-polyclonal-cip2a-antibody-310202415394520.jpg)
![Western Blot: CIP2A Antibody [NB100-74663] - CIP2A is an inhibitor of PP2A-mediated DAPK dephosphorylationRSC96 cells were transfected with control, CIP2A siRNA (A), DKK-CIP2A (B), or DAPK siRNA (C) for 48 h & then exposed to GAS6 (100 ng/ml) for 30 min. PP2A activity & immunoblotting evaluations of DKK, CIP2A, pDAPK, & DAPK were performed. (D) RSC96 cells were incubated with GAS6 (100 ng/ml) for 30 min & co-immunoprecipitation between CIP2A, pDAPK & PP2A was evaluated. Immunoprecipitated PP2A activity was measured. Data are the mean ± SD, & n = 3 for each time point. * p < 0.05, ** p < 0.01, vs. control. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.23978), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-74663_rabbit-polyclonal-cip2a-antibody-310202415363717.jpg)
![Western Blot: CIP2A Antibody [NB100-74663] - Characterization of CIP2A expression in a panel of normal human melanocytes (NHM) & melanoma cell lines. (A) Immunoblot analysis & (B) quantification of protein expression levels of CIP2A (C) CIP2A mRNA expression measured by qRT-PCR. NHM1 line was used as calibrator. (D) Cytoplasmic & nuclear expression of CIP2A in normal melanocytes, primary & metastatic melanoma cell lines assessed by immunoblot analysis & (E) by immunohistochemical staining. CIP2A, cancerous inhibitor of protein phosphatase 2A. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25663244), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-74663_rabbit-polyclonal-cip2a-antibody-31020241539738.jpg)
![Western Blot: CIP2A Antibody [NB100-74663] - GAS6 triggered Schwann cell proliferation primarily through CIP2A & DAPK(A) RSC96 cells were transfected with either control or DAPK siRNA for 48 h & then exposed to GAS6 (100 ng/ml) for 30 min. Immunoblotting evaluations of pAxl, Axl, CIP2A, DAPK, pERK1/2, ERK1/2, pAKT, AKT, Myc & Survivin. (B) RSC96 cells were transfected with either control or CIP2A siRNA for 48 h & then exposed to GAS6 (100 ng/ml) for 30 min. Immunoblotting evaluations of pAxl, Axl, DAPK, pDAPK, pERK1/2, ERK1/2, pAKT, AKT, Myc & Survivin. (C) DAPK or CIP2A was knocked down for 48 h then RSC96 cells were incubated with GAS6 (100 ng/ml) at the indicated hours. Cell viability was analysed via the WST-1 assay. Data are the mean ± SD, & n = 3 for each time point. * p < 0.05, ** p < 0.01 vs. scramble. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.23978), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-74663_rabbit-polyclonal-cip2a-antibody-310202415532020.jpg)
![Western Blot: CIP2A Antibody [NB100-68264] - HPV-16E7 and -58E7 upregulated CIP2A mRNA and protein levels in PHKs(A) Western blot analysis of CIP2A protein level in PHKs expressing HPV-16E7, -58E7, -6E7. Image collected and cropped by CiteAb from the following publication (oncotarget.com/fulltext/2867), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CIP2A-Antibody-Western-Blot-NB100-68264-img0005.jpg "<b>Biological Strategies Validation. </b>Western Blot: CIP2A Antibody [NB100-68264] - HPV-16E7 and -58E7 upregulated CIP2A mRNA and protein levels in PHKs(A) Western blot analysis of CIP2A protein level in PHKs expressing HPV-16E7, -58E7, -6E7. Image collected and cropped by CiteAb from the following publication (oncotarget.com/fulltext/2867), licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Immunohistochemistry-Paraffin: CIP2A Antibody [NB100-68264] - Human colon carcinoma. Antibody used at a dilution of 1:200 (1ug/ml).](http://images.novusbio.com/fullsize/CIP2A-Antibody-Immunohistochemistry-Paraffin-NB100-68264-img0002.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: CIP2A Antibody [NB100-68264] - Whole cell lysate (50 ug) from NIH3T3, TCMK-1, 4T1, CT26.WT, and rat C6 cells.](http://images.novusbio.com/fullsize/CIP2A-Antibody-Western-Blot-NB100-68264-img0003.jpg)
![<b>Independent Antibodies Validation and Biological Strategies Validation.</b>Western Blot: CIP2A Antibody [NB100-68264] - Detection of Human CIP2A on HeLa whole cell lysate using NB100-68264. CIP2A was also immunoprecipitated by rabbit anti-CIP2A antibody NB100-68263.](http://images.novusbio.com/fullsize/CIP2A-Antibody-Western-Blot-NB100-68264-img0001.jpg)
![<b>Genetic Strategies Validation. </b>Knockdown Validated: CIP2A Antibody [NB100-68264] - Knockdown of CIP2A inhibited cell proliferation and DNA synthesis of HPV-16E7-expressing cells with CIP2A siRNA for 48 hr. Image collected and cropped by CiteAb from the following publication (oncotarget.com/fulltext/2867), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CIP2A-Antibody-Knockdown-Validated-NB100-68264-img0004.jpg)
![Western Blot: CIP2A Antibody [NB100-68264] - HPV-16E7 & -58E7 upregulated CIP2A mRNA & protein levels in PHKs(A) Western blot analysis of CIP2A protein level in PHKs expressing HPV-16E7, -58E7, -6E7; & (B) Quantification. (C) qRT-PCR analysis of CIP2A mRNA level in PHKs expressing HPV-16E7, -58E7, -6E7. (D) Western blot analysis of CIP2A protein level in PHKs expressing HPV-16E7 & 16E7 mutants L22A & C24G. Babe, vector control. *, P < 0.05; **, P < 0.01; & ***, P < 0.001. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25650660), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-68264_rabbit-polyclonal-cip2a-antibody-310202415291953.jpg)
![Western Blot: CIP2A Antibody [NB100-68264] - Silencing CIP2A caused decreased Cdk1 & Cdk2 proteins in 16E6‐expressing cells. A, Western blot analysis of CIP2A, Cdk4, Cdk6, cyclin D1, Cdk1, Cdk2, cyclin B1, cyclin A2 & cyclin E1 protein levels in cells expressing HPV‐16E6 transfected with CIP2A siRNA & then treated with PBS or 10 μg/mL bleomycin for 24 h. A representative of 3 independent experiments is shown. B, Quantification of all cell cycle‐related proteins. Data from 3 experiments are summarized. C, Relative mRNA levels of all cell cycle‐related genes determined by qRT‐PCR. Data from 3 experiments are summarized. *, P < .05; **, P < .01 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29893470), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-68264_rabbit-polyclonal-cip2a-antibody-310202415395935.jpg)
![Western Blot: CIP2A Antibody [NB100-68264] - Inhibition of Cdk1 & Cdk2 by CIP2A knockdown in cervical cancer SiHa cells caused G1 arrest. A, Western blot analysis of 16E6, p53 & CIP2A after HPV‐16E6 knockdown in cervical cancer SiHa cells. B, Protein expression of CIP2A, B‐Myb, Cdk1 & Cdk2 in SiHa cells after CIP2A knockdown. Data from a representative of 3 experiments are shown. C, Flow cytometric analysis of SiHa cells with CIP2A knockdown treated with PBS or bleomycin. A representative flow cytometry of 3 independent experiments is shown. D, Quantification of percentages G1 phase cells. Data from 3 experiments are summarized. *, P < .05 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29893470), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-68264_rabbit-polyclonal-cip2a-antibody-310202415334911.jpg)
![Western Blot: CIP2A Antibody [NB100-68264] - Knockdown of CIP2A inhibited cell proliferation & DNA synthesis of HPV-16E7-expressing cells(A) Western blot analysis of protein level of 16E7 & CIP2A in RPE1-16E7 cells & (B) with CIP2A siRNA for 48 hr. (C) CCK8 assay of cell proliferation of RPE1-16E7 cells with CIP2A siRNA. (D) Flow cytometry of cells with CIP2A siRNA & labeled with BrdU for 2 hr, then stained with PI & BrdU; & (E), Quantification. Babe, vector control. **, P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25650660), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-68264_rabbit-polyclonal-cip2a-antibody-31020241534369.jpg)
![Western Blot: CIP2A Antibody [NB100-68264] - Inhibition of Cdk1 & Cdk2 by CIP2A knockdown in cervical cancer SiHa cells caused G1 arrest. A, Western blot analysis of 16E6, p53 & CIP2A after HPV‐16E6 knockdown in cervical cancer SiHa cells. B, Protein expression of CIP2A, B‐Myb, Cdk1 & Cdk2 in SiHa cells after CIP2A knockdown. Data from a representative of 3 experiments are shown. C, Flow cytometric analysis of SiHa cells with CIP2A knockdown treated with PBS or bleomycin. A representative flow cytometry of 3 independent experiments is shown. D, Quantification of percentages G1 phase cells. Data from 3 experiments are summarized. *, P < .05 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29893470), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-68264_rabbit-polyclonal-cip2a-antibody-310202415395929.jpg)
![Western Blot: CIP2A Antibody [NB100-68264] - Inhibition of CIP2A by siRNA impeded cell viability & DNA synthesis in HPV‐16E6–expressing cells. A, Elevated expression of CIP2A protein in 16E6‐expressing RPE1 cells. B, Western blot analysis of CIP2A & p53 proteins after transfection with scrambled siRNA (siCon) or CIP2A siRNA (siCIP2A) for 48 h. A representative of 3 independent experiments is shown. C, Cell viability assay of RPE1‐16E6 cells with CIP2A knockdown. D, Representative flow cytometry of BrdU staining profiles is shown. E, The mean & SD of BrdU‐positive cells from 3 experiments are summarized. **, P < .01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29893470), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-68264_rabbit-polyclonal-cip2a-antibody-310202415384150.jpg)
![Western Blot: CIP2A Antibody [NB100-68264] - CIP2A siRNA knockdown caused G1 arrest & decreased Cdk1 & Cdk2 protein levels in E7-expressing cells(A) Flow cytometry of cells expressing 16E7 transfected with CIP2A siRNA for 48 hr, treated with DMSO control or bleomycin (10 μg/mL) for 24 hr, then stained with PI. G1, S & G2 phases are indicated. (B) Western blot analysis of Cdk1, Cdk2, Cyclin A2, Cdk4, Cdk6, Cyclin D1 protein levels in cells expressing HPV-16E7 transfected with CIP2A siRNA. Babe, vector control. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25650660), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-68264_rabbit-polyclonal-cip2a-antibody-31020241534317.jpg)
![Western Blot: CIP2A Antibody [NB100-68264] - Knockdown of CIP2A inhibited cell proliferation & DNA synthesis of HPV-16E7-expressing cells(A) Western blot analysis of protein level of 16E7 & CIP2A in RPE1-16E7 cells & (B) with CIP2A siRNA for 48 hr. (C) CCK8 assay of cell proliferation of RPE1-16E7 cells with CIP2A siRNA. (D) Flow cytometry of cells with CIP2A siRNA & labeled with BrdU for 2 hr, then stained with PI & BrdU; & (E), Quantification. Babe, vector control. **, P < 0.01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25650660), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-68264_rabbit-polyclonal-cip2a-antibody-3102024153564.jpg)
![Western Blot: CIP2A Antibody [NB100-68264] - Inhibition of CIP2A by siRNA impeded cell viability & DNA synthesis in HPV‐16E6–expressing cells. A, Elevated expression of CIP2A protein in 16E6‐expressing RPE1 cells. B, Western blot analysis of CIP2A & p53 proteins after transfection with scrambled siRNA (siCon) or CIP2A siRNA (siCIP2A) for 48 h. A representative of 3 independent experiments is shown. C, Cell viability assay of RPE1‐16E6 cells with CIP2A knockdown. D, Representative flow cytometry of BrdU staining profiles is shown. E, The mean & SD of BrdU‐positive cells from 3 experiments are summarized. **, P < .01. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29893470), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-68264_rabbit-polyclonal-cip2a-antibody-310202415284523.jpg)
![Western Blot: CIP2A Antibody [NB100-68264] - Regulation of Cdk1 & Cdk2 by CIP2A is dependent on B‐Myb rather than c‐Myc. A, Western blot analysis of CIP2A, c‐Myc, phospho‐S62‐Myc & B‐Myb protein levels in 16E6‐expressing cells after CIP2A knockdown. beta ‐Tubulin was used as a loading control. B, Protein levels of B‐Myb, c‐Myc & phospho‐S62‐Myc in 16E6‐expressing PHKs & (C) RPE1 cells. D, Protein levels of B‐Myb, Cdk1 & Cdk2, CIP2A & p53 in 16E6‐expressing cells after B‐Myb knockdown with siRNA. Data from a representative of 3 experiments are shown. E, Knockdown of B‐Myb down‐regulates Cdk1 & Cdk2 luciferase reporter activities. RPE1 cells were cotransfected with the Cdk1 or Cdk2 promoter‐luciferase constructs & renilla luciferase control plasmid together with B‐Myb siRNA plasmid. Cells were harvested after 48 h, & lysates were assayed for luciferase activity. F, Flow cytometric analysis of 16E6‐expressing cells transfected with B‐Myb siRNA treated with PBS or bleomycin. G1, S & G2 phases are indicated. A representative flow cytometry of 3 independent experiments is shown. G, Quantification of percentages G1 phase cells. Data from 3 experiments are summarized. H, Western blot analysis of B‐Myb, Cdk1 & Cdk2 in B‐Myb–overexpressing CIP2A knockdown cells. Data from a representative of 3 experiments are shown. *, P < .05; ***, P < .001 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29893470), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-68264_rabbit-polyclonal-cip2a-antibody-31020241612638.jpg)
![Western Blot: CIP2A Antibody [NB100-68264] - Induction of CIP2A mRNA & protein expression by HPV‐16E6 in PHKs. A, mRNA expression of HPV‐16E6 in PHKs expressing 16E6 & F2V using beta ‐actin as a loading control. B, Protein levels of HPV‐16E6, p53 & p21 in PHKs expressing 16E6 & F2V. Expression of GAPDH was used as a loading control. A representative of 2 independent experiments is shown. C, HPV‐16E6 expression leads to increased protein expression of CIP2A in PHKs. Data from a representative of 3 experiments are shown. D, Data from 3 experiments are summarized. E, Relative CIP2A mRNA expression was determined by qRT‐PCR in the above cells. Data from 3 experiments are summarized. The mean & standard deviation (SD) of 3 independent experiments are shown. Babe, pBabe‐puromycin vector. *, P < .05; **, P < .01; & ***, P < .001 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29893470), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-68264_rabbit-polyclonal-cip2a-antibody-3102024161263.jpg)
![Western Blot: CIP2A Antibody [NB100-68264] - Regulation of Cdk1 & Cdk2 by CIP2A is dependent on B‐Myb rather than c‐Myc. A, Western blot analysis of CIP2A, c‐Myc, phospho‐S62‐Myc & B‐Myb protein levels in 16E6‐expressing cells after CIP2A knockdown. beta ‐Tubulin was used as a loading control. B, Protein levels of B‐Myb, c‐Myc & phospho‐S62‐Myc in 16E6‐expressing PHKs & (C) RPE1 cells. D, Protein levels of B‐Myb, Cdk1 & Cdk2, CIP2A & p53 in 16E6‐expressing cells after B‐Myb knockdown with siRNA. Data from a representative of 3 experiments are shown. E, Knockdown of B‐Myb down‐regulates Cdk1 & Cdk2 luciferase reporter activities. RPE1 cells were cotransfected with the Cdk1 or Cdk2 promoter‐luciferase constructs & renilla luciferase control plasmid together with B‐Myb siRNA plasmid. Cells were harvested after 48 h, & lysates were assayed for luciferase activity. F, Flow cytometric analysis of 16E6‐expressing cells transfected with B‐Myb siRNA treated with PBS or bleomycin. G1, S & G2 phases are indicated. A representative flow cytometry of 3 independent experiments is shown. G, Quantification of percentages G1 phase cells. Data from 3 experiments are summarized. H, Western blot analysis of B‐Myb, Cdk1 & Cdk2 in B‐Myb–overexpressing CIP2A knockdown cells. Data from a representative of 3 experiments are shown. *, P < .05; ***, P < .001 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29893470), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-68264_rabbit-polyclonal-cip2a-antibody-310202415535140.jpg)
![Immunocytochemistry/Immunofluorescence: CIP2A Antibody [NBP2-48710] - Analysis of human cell line A-431 shows positivity in plasma membrane & cytoplasm.](http://images.novusbio.com/fullsize/CIP2A-Antibody-Immunocytochemistry-Immunofluorescence-NBP2-48710-img0001.jpg "Immunocytochemistry/Immunofluorescence: CIP2A Antibody [NBP2-48710] - Analysis of human cell line A-431 shows positivity in plasma membrane & cytoplasm.")
![Immunohistochemistry-Paraffin: CIP2A Antibody [NBP2-48710] - Staining of human testis shows moderate cytoplasmic positivity in cells in seminiferous ducts.](http://images.novusbio.com/fullsize/CIP2A-Antibody-Immunohistochemistry-Paraffin-NBP2-48710-img0003.jpg)
![Western Blot: CIP2A Antibody [NBP2-92975] - analysis of NIH/3T3, using KIAA1524 Rabbit pAb at 1:1000 dilution.Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution.Lysates/proteins: 25 ug per lane.Blocking buffer: 3% nonfat dry milk in TBST.Detection: ECL Basic Kit. Exposure time: 20s.](http://images.novusbio.com/fullsize/antibody/nbp2-92975_rabbit-polyclonal-cip2a-antibody-western-blot-811202383044..jpg "Western Blot: CIP2A Antibody [NBP2-92975] - analysis of NIH/3T3, using KIAA1524 Rabbit pAb at 1:1000 dilution.Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution.Lysates/proteins: 25 ug per lane.Blocking buffer: 3% nonfat dry milk in TBST.Detection: ECL Basic Kit. Exposure time: 20s.")